This study assessed the utility of cerebrospinal fluid (CSF) neurofilament light (NfL) in Alzheimer's disease (AD) diagnosis, its association with amyloid and tau pathology, as well as its potential to predict brain atrophy, cognition, and amyloid accumulation.
INTRODUCTION
Alzheimer's disease (AD) is the most common form of dementia. 1 The use of positron emission tomography (PET) imaging has not only led to the possibility of diagnosis pre-mortem, but also to the confirmation that AD pathology develops many years before the symptoms appear. 2 However, PET diagnostic methods have limited utility due to the high cost and poor accessibility. For more cost-effective diagnostic tools, a significant amount of research has been done to explore and validate cerebrospinal fluid (CSF) biomarkers. 3 This has led to CSF biomarkers being included in the diagnostic criteria for AD in 2011, by the National Institute on Aging (NIA) and the Alzheimer's Association (AA), 4 and the International Working Group (IWG) in 2014. 5 In addition, blood biomarkers have been investigated, as well as eye imaging; however, these approaches although promising require considerably more evidence to be as convincing as the gold standard CSF biomarkers. [6] [7] [8] Evidence indicates that AD is a disease of multiple etiologies, with numerous risk factors that overlap with respect to metabolic and pathological changes they cause, yet together direct and/or accelerate the trajectory of AD dementia. 3, 9 The multiple pathological changes are associated with specific biomolecules that might serve as biomarkers for making a diagnosis, and as indicators of changes that occur with disease progression. This article focuses on CSF neurofilament light (NfL) chain protein and its potential as an AD biomarker. NfL has emerged as one of the most promising CSF markers of neurodegeneration, for diagnostic purposes, and in particular for studying disease neuropathological progression. [10] [11] [12] [13] [14] Elevated CSF NfL levels are linked to white matter changes in the brain, which reflects the fact that NfL is a biomarker of axonal degeneration. 15 Elevated levels are associated with rate of hippocampal atrophy in cognitively healthy individuals, including those at risk for AD. 16 In addition recent studies have reported elevated levels of NfL in the plasma of AD subjects. 17, 18 Neurofilaments are phosphoproteins that are synthesized in the cell bodies and then translocated to the axons. 19 The functions of neurofilaments depend on their state of phosphorylation. 20 They are hetero-polymeric proteins comprising four subunits: neurofilament heavy (NfH), neurofilament medium (NfM), and neurofilament light (NfL) polypeptides and -internexin or peripherin. 21 Neurofilaments are found particularly in neuronal axons, keeping the myelinated axons structurally stable and playing an essential role in the growth and impulse conduction along the axons. 21 They also act as skeletal supports, helping to maintain the shape of neurons. 22 Neuronal damage in neurodegenerative diseases, as well as in acute brain injury, would likely result in the release of neurofilaments into the CSF.
The present study aimed to investigate the utility of CSF NfL levels in the diagnosis of AD and in the assessment of brain amyloid load, atrophy, and cognition. The study was conducted by using baseline CSF samples from participants in the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL). The aims of the present study were as follows: (1) to assess the diagnostic utility of NfL in distinguishing AD from mild cognitive impairment (MCI) and healthy controls (HCs); (2) to assess the diagnostic accuracy of NfL (alone or in combination with CSF amyloid [A 42], CSF total tau [T-tau], or phosphorylated tau [P-tau]) in differentiating AD from controls using receiver operating characteristic (ROC) curve analysis; (3) to assess whether there is an association between CSF NfL levels and amyloid levels, tau pathology, and/or brain volumes; (4) to assess whether CSF NfL levels predict baseline brain amyloid load, brain atrophy, and cognition; and (5) to assess whether NfL predicts change in brain amyloid burden.
MATERIALS AND METHODS

Participants
This study reports on data and samples obtained from 221 participants recruited as a part of the AIBL study (http://aibl.csiro.au/), who had their CSF collected at baseline between 2009 and 2016. Among these, 100 were recruited at the time of the study inception and the remaining participants were recruited during enrichment of the cohort. The AIBL is a prospective, longitudinal study that assesses the participants at 18-month intervals, investigating changes in biomarkers, cognition, and other parameters. The study was initiated in 2006 to investigate potential biomarkers, cognitive parameters, and lifestyle factors associated with AD. The study consists of individuals categorized as AD, MCI, and HC. 23 The classification of AD is based on the National were clinically classified as HC (n = 159), MCI (n = 34), and AD (n = 28).
Age, gender, and apolipoprotein E (APOE) genotype data were assessed as part of the cohort demographic characterization. The AIBL has more than 2400 participants, and lumber punctures (LPs) have been done on over 200 participants only, because about one in 10 agreed to have one. for MRI image acquisition, brain segmentation, and volumes has been described elsewhere. 28 
Brain imaging and cognitive assessment
Sample collection and storage
Future directions:
We further aim to evaluate the utility of CSF NfL to predict disease onset in HCs that progress to dementia, as well as its utility for predicting rate of cognitive decline in individuals with AD. 
Biomarker measurement
Statistical analysis
Analysis of covariance (ANCOVA) was used to assess for differences in at least one pair of continuous mean CSF or brain volumetric mea- 
RESULTS
Diagnostic utility of NfL for distinguishing different diagnostic groups
Levels of NfL in the CSF samples of the 221 participants were quantified. Table 1 shows the summary of the demographics and biomarker data of the participants. Two samples were eliminated from the analysis owing to their influence in the diagnostic plots even after natural logarithm transformation of the CSF NfL. Both samples were of AD-affected participants and had very high values. Therefore, analysis was carried out using the data from the remaining 219 participants, to assess the differences between any pair of participant groups after log transformation of the CSF measures. NfL levels were significantly increased in AD as compared to HC (P < .001), as well as in MCI compared to HC (P = .008). Levels were not significantly different between the AD and MCI groups (Figure 1, P = .139 ). The ratio of CSF NfL to CSF A 42 (NfL/A 42), was significantly elevated in AD compared to both MCI (P = .007) and HC (P < .001). In addition, NfL/A 42 was significantly elevated in MCI compared to HC (P < .001). Similar results were observed for other biomarkers (CSF A 42, T-tau, P-tau) including the ratios (T-tau/A 42, P-tau/A 42), as shown in Table 1 .
ROC curve analyses were undertaken for all 221 samples, to assess the ability of individual CSF measures, as well as different ratios to differentiate AD from HC (results shown in Table 2 ). CSF NfL differentiated AD from controls with an area under the ROC curve (AUC) of 0.84 and a sensitivity and specificity of 81.5% and 79.7%, respectively, which is comparable to the results obtained using CSF A 42, but higher than the biomarkers of tau pathology ( 
Association of NfL with amyloid and tau pathology
To assess the association of NfL with amyloid pathology (via CSF A 42), the extent of correlation between CSF NfL and CSF A 42 (both transformed using natural logarithm) was evaluated. There was no significant correlation between NfL and CSF A 42 (r = −0.122, P = .072). The association of NfL with tau pathology was assessed by the extent of correlation between CSF NfL and CSF T-tau and P-tau after transformation using natural logarithm. CSF NfL was significantly correlated with CSF T-tau (r = 0.52, P < .001) and P-tau (r = 0.43, P < .001).
The correlations remained significant even after controlling for age and gender.
Association of NfL with brain atrophy
Associations between CSF NfL and brain volumes (cortical gray matter, white matter, ventricular and hippocampal volumes) were investigated, after transforming to natural logarithm. There was a significant negative moderate correlation between cortical gray matter volume and NfL (r = −0.38, P < .001) and a significant weak negative correlation between hippocampal volume and NfL (r = −0.27, P < .001). CSF NfL levels were not associated significantly with either white matter Because there was a significant moderate correlation between CSF NfL and cortical gray matter volume, the utility of CSF NfL as a predictor of baseline gray matter volume was assessed further.
Utility of CSF NfL levels as an indicator of amyloid burden, brain atrophy, and cognition
Individually, each of the CSF biomarkers significantly predicted baseline amyloid load as measured by log SUVR, brain atrophy (measured by cortical gray matter volume), as well as baseline cognition (measured by MMSE), while controlling for covariates in a linear regression (Table 3 ). Higher levels of CSF NfL ( = 0.11, standardized = 0.24, P = .001) and the larger NfL/A 42 ratio ( = 0.10, standardized = 0.51, P < .001) were associated with significantly higher baseline were combined as ratios, to determine whether they could predict baseline brain amyloid load better when evaluated together. A model including the ratio of CSF NfL and A 42 accounted for 40% variability in baseline amyloid load. The models including the ratio of CSF T-tau or P-tau and CSF A 42 explained more of the variability in baseline amyloid load (50% and 52%, respectively).
Among the CSF measures, the individual measures and derived ratios were all significantly associated with predicted baseline brain volume or brain atrophy, as measured by cortical gray matter volume, upon controlling for covariates, except CSF P-tau (Table 3 ). CSF NfL ( = −10.15, standardized = −0.29, P < .001) and NfL/A 42 ratio ( = −6.99, standardized = −0.43, P < .001) correlated significantly with smaller baseline cortical gray matter volume. The ratio of CSF NfL and A 42 levels (R 2 = 32%) was a better predictor of cortical brain atrophy than either of these measures individually. Among the individual measures, CSF NfL, and among the ratios, NfL/A 42, were the best predictors of brain atrophy.
All CSF measures and the ratios derived from these measures significantly predicted baseline cognition as measured by MMSE, even after controlling for covariates (Table 3) 
Utility of baseline CSF NfL to predict change in amyloid accumulation
Baseline CSF NfL was not associated significantly with the change in 
DISCUSSION
Consistent with findings from other studies, the current study shows that CSF NfL is a promising biomarker of AD-related neurodegeneration, demonstrating it is potentially useful in both AD diagnosis and for studying the disease's preclinical stages of pathogenic progression. 10, 13, 14, 31 CSF NfL levels were significantly higher in AD patients as compared to HCs. Moreover, NfL distinguished AD from HC with reasonably high sensitivity and specificity. As seen in Table 2 , the
AUC of NfL can distinguish AD from HC as effectively as T-tau and CSF
A 42, and it can distinguish AD from HC with higher AUC than P-tau levels. CSF NfL levels correlated significantly with the biomarkers of tau pathology, as well as baseline cortical gray matter volume and hippocampal volume. Baseline NfL levels significantly predicted baseline cortical gray matter volume and cognitive scores. NfL/A 42 was the best predictor of brain atrophy and was among the best predictors of cognitive scores. These results indicate that CSF NfL levels can be used in the assessment of cognitive decline, brain atrophy, and the stage of neurodegeneration along the disease trajectory.
There was little correlation found between CSF NfL and CSF A 42 levels. CSF NfL was a significant but weaker predictor of baseline amyloid load and did not predict longitudinal change in amyloid accumulation. This implies that CSF NfL levels are more likely reflective of neurodegeneration and brain atrophy than the developing amyloid pathology. Nevertheless, the ratio of CSF NfL/A 42 had a much higher diagnostic accuracy in distinguishing patients with AD from controls.
This highlights the fact that although developing amyloid pathology and levels of axonal degeneration correlate with each other to a lesser extent than some of the other variables tested here, the two pathologies were found to develop concurrently along the disease trajectory in our cohort.
In a recent study of mouse models of neurodegenerative diseases, both CSF and plasma NfL levels increased with the onset and progression of proteopathic lesions in the brain. 32 These increases were seen in the models of several neurodegenerative conditions, including -synucleinopathies, tauopathies, and amyloidoses such as AD. The CSF NfL levels were elevated in the mice before neurological signs of neurodegeneration were evident, supporting the concept that NfL changes occur early in the disease process and can act as a preclinical disease biomarker. 32 The study also showed that the increases in CSF NfL levels normally found in an AD mouse model (APPPS1) were much lower following 6 months of treatment with a -secretase 1 (BACE1) inhibitor, indicating that NfL levels might be useful as a treatment response biomarker. 32 Therefore, NfL could be used as a preclinical marker of neurodegeneration (axonal degeneration), and in conjunction with the biomarkers of tau and amyloid pathology could provide specific disease diagnosis. The lack of significant difference in NfL levels between MCI and AD patients suggest that axonal degeneration is too compromised following the onset of clinical symptoms, and further studies will determine if the range of CSF NfL levels seen within the MCI group of patients reflects neurodegeneration stage.
NfL is a non-specific marker of axonal degeneration elevated in a range of neurodegenerative and neurological disorders such as synucleinopathies, amyotrophic lateral sclerosis, 33 frontotemporal dementia (FTD), 34 Creutzfeldt-Jakob disease, 35 and vascular dementia. 36 However, studies have shown that the levels vary between different disorders, [36] [37] [38] and further studies will evaluate the potential of NfL as a marker in differential diagnosis, when used in combination with disease-specific biomarkers, such as A 42. Being a non-specific neurodegeneration marker, it is not associated with amyloid accumulation. Of interest, CSF NfL levels seem to reflect the intensity of axonal degeneration in all neurodegenerative conditions, as reflected in cognition scores, 31 thus disease-specific research into the value of CSF NfL levels will determine the value of using this biomarker in other neurodegenerative conditions.
It can be concluded that CSF NfL, as a biomarker of neurodegeneration in AD, is of similar sensitivity to CSF A 42 and tau biomarkers. However, CSF NfL should be used in combination with these more disease-specific biomarkers, as it is a general biomarker of neurodegeneration and not specific to any particular neurodegenerative disease. NfL predicts cortical gray matter volume loss, as well as cognitive impairment. Therefore, NfL can be used as a marker of neurodegeneration that associates with cognitive impairment and brain atrophy, along the disease trajectory. It could serve as a better predictor of disease progression, as a surrogate marker of neurodegenerative changes, in clinical trials.
Recent studies suggest that plasma NfL levels are of diagnostic value in AD, and to a greater extent than in other conditions, such as Parkinson disease. 39 In familial AD cases, serum NfL levels have been shown to increase at preclinical stages, correlating with measures of disease stage and severity, 40 with more recent longitudinal studies by the same research group indicating serum NfL starts to increase more than a decade before symptom onset in familial AD cases. 41 However, blood NfL is thought to originate from the CSF, and blood levels of NfL correlate well with levels seen in the CSF, although they rise to a lesser extent and later than in the CSF. 32 These studies are encouraging; however, studies are still needed to evaluate the diagnostic value of both blood and CSF levels of NfL in preclinical sporadic AD cases.
